Project Grant HT9425261E080
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded Icahn School of Medicine at Mount Sinai a $1.25M project grant under the Military Medical Research and Development program (CFDA 12.420) effective May 1, 2026 through April 30, 2029. The award supports research and development services focused on first-in-class degraders targeting oncogenic PTK6 (protein tyrosine kinase 6) in triple-negative breast cancer. This three-year research initiative aligns with the DHA's mission to...
- Federal Grant Award Summary Icahn School of Medicine at Mount Sinai received a $1,249,998 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period July 1, 2026 through June 30, 2029. The award supports research focused on targeting KDM5 histone demethylases as a therapeutic approach to treat breast cancer. This research falls within the DHA's broader mission to advance innovative biomedical solutions...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Icahn School of Medicine at Mount Sinai a $507,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2027. The award supports research to investigate tumor-intrinsic epigenetic mechanisms that modulate antitumor immune responses in metastatic prostate cancer. This research initiative advances the DHA's mission to transform healthcare...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded Icahn School of Medicine at Mount Sinai a $1.23M Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025 through June 30, 2028. The award supports biomarker development research focused on refining an individualized risk-adapted approach to bladder-sparing treatment for muscle-invasive bladder cancer. This research initiative aims to advance clinical decision-making and...
- Federal Grant Award Summary Icahn School of Medicine at Mount Sinai (ISMMS) received a $505,270 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded on September 30, 2025, with a completion date of September 29, 2027. The award supports research investigating the impact of reprogrammed PIK3R1-insulin-glucose metabolism pathway in lethal prostate cancer to develop therapeutic strategy. This research aligns with the...
- Federal Project Grant Summary Icahn School of Medicine at Mount Sinai received a $633,750 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), awarded August 1, 2025, with a completion date of July 31, 2028. The grant supports research investigating the interplay between sensory neurons and natural killer (NK) cells during breast cancer metastatic dormancy. This three-year research initiative aligns with the Defense Health...
- Grant Award Summary Icahn School of Medicine at Mount Sinai received a $633,750 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period August 1, 2025 through July 31, 2028. The award funds research investigating the interplay between sensory neurons and natural killer (NK) cells during breast cancer metastatic dormancy. This research contributes to the DHA's broader mission of transforming healthcare for...
- Federal Project Grant Award Summary Icahn School of Medicine at Mount Sinai received a $591,500 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period August 1, 2025 through July 31, 2027. The award supports research titled "Decoding the Tumor Microenvironment Remodeling of Cancer Vaccine Treatment in Pleural Mesothelioma," to be conducted at the institution's New York, NY location. This project...
- Federal Project Grant Award Summary Icahn School of Medicine at Mount Sinai received a $2.18M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to investigate metabolites and metabolic pathways associated with Crohn disease risk. The award, dated June 1, 2025, supports a four-year research initiative extending through June 30, 2029, conducted at the institution's New York campus. This biomedical research project aligns...
- Federal Project Grant Award Summary Icahn School of Medicine at Mount Sinai (ISMMS) received a $466,809 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025, through August 31, 2028. The award supports research titled "Identification of Recessive Prostate Cancer Risk Alleles in the Million Veterans Program," which will be conducted at ISMMS's facility in New York, NY. This...
The Defense Health Agency (DHA) awarded Icahn School of Medicine at Mount Sinai a $1.25 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) on May 1, 2026, with a completion date of April 30, 2029. The grant funds research to develop first-in-class protein degraders targeting PTK6 (protein tyrosine kinase 6) as a therapeutic approach for triple-negative breast cancer. This research directly aligns with the DHA's mission to transform healthcare for service members and the American public through innovative biomedical solutions addressing critical oncology challenges. Under this award, Mount Sinai's research team will conduct hypothesis-driven translational research combining drug discovery, biochemical characterization, and therapeutic development activities to advance PTK6-targeting degrader technology toward clinical application. The three-year performance period supports the institution's established capabilities in cancer biology research and therapeutic innovation, leveraging Mount Sinai's recognized strengths in executing complex research programs funded through the Military Medical Research and Development program's competitive peer and programmatic review process.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.3m | 5/3/26 |